論文

国際誌
2021年1月

The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.

Journal of molecular medicine (Berlin, Germany)
  • Kota Araki
  • ,
  • Rie Kinoshita
  • ,
  • Nahoko Tomonobu
  • ,
  • Yuma Gohara
  • ,
  • Shuta Tomida
  • ,
  • Yuta Takahashi
  • ,
  • Satoru Senoo
  • ,
  • Akihiko Taniguchi
  • ,
  • Junko Itano
  • ,
  • Ken-Ichi Yamamoto
  • ,
  • Hitoshi Murata
  • ,
  • Ken Suzawa
  • ,
  • Kazuhiko Shien
  • ,
  • Hiromasa Yamamoto
  • ,
  • Mikio Okazaki
  • ,
  • Seiichiro Sugimoto
  • ,
  • Kouichi Ichimura
  • ,
  • Masahiro Nishibori
  • ,
  • Nobuaki Miyahara
  • ,
  • Shinichi Toyooka
  • ,
  • Masakiyo Sakaguchi

99
1
開始ページ
131
終了ページ
145
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s00109-020-02001-x

In patients with interstitial pneumonia, pulmonary fibrosis is an irreversible condition that can cause respiratory failure. Novel treatments for pulmonary fibrosis are necessary. Inflammation is thought to activate lung fibroblasts, resulting in pulmonary fibrosis. Of the known inflammatory molecules, we have focused on S100A8/A9 from the onset of inflammation to the subsequent progression of inflammation. Our findings confirmed the high expression of S100A8/A9 in specimens from patients with pulmonary fibrosis. An active role of S100A8/A9 was demonstrated not only in the proliferation of fibroblasts but also in the fibroblasts' differentiation to myofibroblasts (the active form of fibroblasts). S100A8/A9 also forced fibroblasts to upregulate the production of collagen. These effects were induced via the receptor of S100A8/A9, i.e., the receptor for advanced glycation end products (RAGE), on fibroblasts. The anti-S100A8/A9 neutralizing antibody inhibited the effects of S100A8/A9 on fibroblasts and suppressed the progression of fibrosis in bleomycin (BLM)-induced pulmonary fibrosis mouse model. Our findings strongly suggest a crucial role of S100A8/A9 in pulmonary fibrosis and the usefulness of S100A8/A9-targeting therapy for fibrosis interstitial pneumonia. HIGHLIGHTS: S100A8/A9 level is highly upregulated in the IPF patients' lungs as well as the blood. S100A8/A9 promotes not only the growth of fibroblasts but also differentiation to myofibroblasts. The cell surface RAGE acts as a crucial receptor to the extracellular S100A8/A9 in fibroblasts. The anti-S100A8/A9 antibody effectively suppresses the progression of IPF in a mouse model. In idiopathic pulmonary fibrosis (IPF), S100A8/A9, a heterodimer composed of S100A8 and S100A9 proteins, plays a crucial role in the onset of inflammation and the subsequent formation of a feed-forward inflammatory loop that promotes fibrosis. (1) The local, pronounced increase in S100A8/A9 in the injured inflammatory lung region-which is provided mainly by the activated neutrophils and macrophages-exerts strong inflammatory signals accompanied by dozens of inflammatory soluble factors including cytokines, chemokines, and growth factors that further act to produce and secrete S100A8/A9, eventually making a sustainable inflammatory circuit that supplies an indefinite presence of S100A8/A9 in the extracellular space with a mal-increased level. (2) The elevated S100A8/A9 compels fibroblasts to activate through receptor for advanced glycation end products (RAGE), one of the major S100A8/A9 receptors, resulting in the activation of NFκB, leading to fibroblast mal-events (e.g., elevated cell proliferation and transdifferentiation to myofibroblasts) that actively produce not only inflammatory cytokines but also collagen matrices. (3) Finally, the S100A8/A9-derived activation of lung fibroblasts under a chronic inflammation state leads to fibrosis events and constantly worsens fibrosis in the lung. Taken together, these findings suggest that the extracellular S100A8/A9 heterodimer protein is a novel mainstay soluble factor for IPF that exerts many functions as described above (1-3). Against this background, we herein applied the developed S100A8/A9 neutralizing antibody to prevent IPF. The IPF imitating lung fibrosis in an IPF mouse model was effectively blocked by treatment with the antibody, leading to enhanced survival. The developed S100A8/A9 antibody, as an innovative novel biologic, may help shed light on the difficulties encountered with IPF therapy in clinical settings.

リンク情報
DOI
https://doi.org/10.1007/s00109-020-02001-x
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33169236

エクスポート
BibTeX RIS